MODULATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANCE - A REVIEW

被引:185
作者
TIMMERBOSSCHA, H [1 ]
MULDER, NH [1 ]
DEVRIES, EGE [1 ]
机构
[1] UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV MED ONCOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS
关键词
D O I
10.1038/bjc.1992.249
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this review an inventory is made of agents used to circumvent cis-diamminedichloroplatinum(II) (CDDP) resistance in vitro and in vivo. Agents that affect CDDP accumulation and membrane related systems, cytoplasmic defense mechanisms, as well as DNA accessibility and repair are reviewed. In resistant cell lines that have decreased accumulation, this can be restored by hyperthermic treatment. With or without effects on accumulation compounds that affect cell signal transduction often increase CDDP cytotoxicity. Calcium channel blockers and calmodulin inhibitors do not seem to be uniformly good modulators of CDDP resistance. For transduction modulators as well as cellular calcium affecting agents mechanisms are mainly unclear or controversial. Glutathione appears, with the now available agents, to be the most promising target for modulation of cytoplasmic defense mechanisms. At the nuclear level the inhibition of DNA repair related enzymes as well as the use of modified nucleosides to interfere with repair is studied in various cell lines. Results with these agents suggest opportunities for clinically feasible cytotoxicity modulation. DNA accessibility could in vitro be affected, but seems to be an unreliable target for modulation. Whenever possible the resistance mechanism affected and the mode of action of the modulator are discussed. As an alternative for modulation another method of overcoming CDDP resistance namely the application of CDDP analogues is considered.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 143 条
[1]  
ADNREWS PA, 1991, CANCER RES, V51, P3677
[2]   CISPLATIN PRECEDED BY CONCURRENT CYTARABINE AND HYDROXYUREA - A PILOT-STUDY BASED ON AN INVITRO MODEL [J].
ALBAIN, KS ;
SWINNEN, LJ ;
ERICKSON, LC ;
STIFF, PJ ;
FISHER, RI .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (01) :33-40
[3]  
ALLEN ED, 1986, CANCER RES, V46, P3550
[4]  
ANDREWS PA, 1986, MOL PHARMACOL, V30, P643
[5]  
ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[6]  
ANDREWS PA, 1991, 6TH P INT S PLAT MET, P37
[7]  
BABA H, 1989, CANCER RES, V49, P7041
[8]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[9]  
BASU A, 1991, CANCER RES, V51, P893
[10]  
BASU A, 1990, J BIOL CHEM, V265, P8451